NCT07434947Recruiting
Study of Three Endpoints to Assess the Benefit of Rehabilitation in Patients With Advanced Non-small Cell Lung Cancer Controlled After at Least 6 Months of Systemic Treatment
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The objective of this study is to identify an outcome that is relevant for assessing the benefit of rehabilitation in patients with advanced or metastatic non-small cell lung cancer whose disease has been stable or responding for at least 6 months with systemic treatment. Many people living with lung cancer experience asthenia, which reduces daily activity, independence, and quality of life. Regular physical activity (PA) is recommended for the management of all chronic diseases, including cancer. PA can be done independently by the patient or supervised by adapted physical activity instructors (EAPA) at home or in a day hospital (HDJ) in medical and rehabilitation care departments (SMR), where it is covered by social security. Rehabilitation program and physical activity may help improve strength, function, and social participation, for patients with non-small cell lung cancer . In this study, patients will participate in a 3-month rehabilitation program. We will measure quality of life, hand grip strength, and the Five Times Sit to Stand Test, before and after the program. Other measures will include daily step counts, nutrition, overall health status, continuation of cancer treatment, program adherence, and participant satisfaction. About 63 participants will be recruited in several hospitals, including CHUGA, CHMS and CHANGE. This patients will be able to choose a program that suits them and is available as part of they care. We are expecting 50 patients to participate in one of the rehabilitation program. The main goal is to identify the most useful outcomes to assess in future studies that will compare different rehabilitation approaches for people with lung cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 63 (estimated)
- First submitted
- 22 Dec 2025
- Start date
- 15 Apr 2026
- Primary completion date
- 14 Oct 2027
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Lung cancer
- NCT number
- NCT07434947
What you commit to
- Study type: Observational
- Planned participants: 63
- From 15 Apr 2026 to the primary completion date, 14 Oct 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with an absolute contraindication to physical activity at the time of consultation (e.g., unstable angina; acute intercurrent event...)
Age
- Initial management of the tumor disease started ≥ 2 years ago
Other
- Residual toxicity of grade ≥ 2
- Estimated life expectancy less than 6 months (at the discretion of the investigator)
- Subject currently in an exclusion period from another study or participating in an interventional study
Who the study is looking for
- Adult patients treated for NSCLC at CHUGA, CHMS, or CHANGE
- Locally advanced or metastatic NSCLC
- Tumor disease controlled for at least 6 months following any type of anti-tumor treatment
- ECOG Performance Status 0 to 2
- Patient reporting functional complaints related to physical activity
- Covered by the national health insurance system
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Annecy Genevois Coordinator of this site? Confirm its status | Annecy | France | Not yet recruiting |
| CH Métropole-Savoie Coordinator of this site? Confirm its status | Chambéry | France | Recruiting |
| CHU Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.